Navigation Links
Vermillion Receives NASDAQ Notice of Non-Compliance

FREMONT, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML) announced that on February 22, 2008 it received a letter from The NASDAQ Stock Market LLC that indicated the Company is not in compliance with Marketplace Rule 4310(c)(3), which requires it to have (i) a minimum of $2,500,000 in stockholders' equity; (ii) $35,000,000 in market value of listed securities; or (iii) $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.

In accordance with Marketplace Rule 4310(c)(8)(C), the Company has been afforded 30 calendar days, or until March 24, 2008, to regain compliance. If, any time prior to March 24, 2008, the market value of listed securities of the Company's common stock is $35,000,000 or more for a minimum of 10 consecutive business days, NASDAQ may determine that the Company has regained compliance. If the Company does not regain compliance by March 24, 2008, NASDAQ will provide written notification that the Company's securities are subject to delisting. At that time, the Company may request a hearing before a NASDAQ Listing Qualifications Panel. The Company's securities would remain listed pending the issuance of a decision by the Panel.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, hematology, cardiology and women's health with an initial focus in ovarian cancer. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
2. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
5. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
6. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
7. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
8. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
9. Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg
10. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" ... Norman C.W. Wong to its Board of Directors ... to Zenith with a wealth of experience as co-founder of ... biology. --> --> Dr. ... Epigenetics, board of directors. Zenith,s long standing expertise in epigenetics ...
(Date:11/30/2015)... 2015  Champions Oncology, Inc. (CSBR), engaged in the ... the development and use of oncology drugs, today announced ... be presenting at the LD MICRO Investor Conference on ... (PST).  The conference, held at the Luxe Sunset Bel ... , will feature 200 small/micro-cap companies and is expected ...
(Date:11/30/2015)... Nov. 30, 2015  HUYA Bioscience International, the leader ... pharmaceutical innovations, today announced it has signed a ... (KDDF) to foster collaboration between KDDF and HUYA with ... of healthcare products for the global market. ... source of new innovative preclinical and clinical stage compounds. ...
(Date:11/30/2015)... and MAGDEBURG, Germany , November ... NeuroRehabilitation (ECNR) in Vienna, Austria ... European Congress of NeuroRehabilitation (ECNR) in Vienna, ... --> NovaVision, a wholly owned subsidiary of Vycor Medical, ... version of its Internet-delivered NovaVision Therapy Suite at the ...
Breaking Biology Technology:
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
Breaking Biology News(10 mins):